In the CREDENCE study, canagliflozin “consistently reduced the relative risk of kidney events in people with diabetic kidney disease in both sexes and across age subgroups,” the investigators conclude. “Owing to higher background risk, the absolute reduction in adverse kidney outcomes was greater in younger participants.”
Secondary analysis of CREDENCE’s daily doses of canagliflozin 100 mg or placebo looked at a primary composite outcome of kidney failure, doubling of serum creatinine, or death due to kidney or cardiovascular disease. “The mean age of the cohort was 63.0 ± 9.2 years and 34% were female,” the authors write. “Older age and female sex were independently associated with a lower risk of the composite of adverse kidney outcomes. There was no evidence that the effect of canagliflozin on the primary outcome (a composite of kidney failure, a doubling of the serum creatinine, or death from kidney or cardiovascular causes) differed between age groups (HR 0.67, 95% CI 0.52 to 0.87; HR 0.63, 95% CI 0.48 to 0.82; and HR 0.89, 95% CI 0.61 to 1.29; for the <60, 60-69, and ≥70 year groups, respectively; Pinteraction=0.3); or among females and males (HR 0.71, 95% CI 0.54 to 0.95; and HR 0.69, 95% CI 0.56 to 0.84, respectively; Pinteraction=0.8). No differences in safety outcomes by age group or sex were observed.”